WO2004108076A3 - Composes de benzamide anti-vih - Google Patents

Composes de benzamide anti-vih Download PDF

Info

Publication number
WO2004108076A3
WO2004108076A3 PCT/US2004/015791 US2004015791W WO2004108076A3 WO 2004108076 A3 WO2004108076 A3 WO 2004108076A3 US 2004015791 W US2004015791 W US 2004015791W WO 2004108076 A3 WO2004108076 A3 WO 2004108076A3
Authority
WO
WIPO (PCT)
Prior art keywords
infectivity
hiv
mammal
benzamide compounds
retrovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/015791
Other languages
English (en)
Other versions
WO2004108076A2 (fr
Inventor
Vassilios Papadopoulos
Janet Greeson
Laurent Lecanu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Samaritan Pharmaceuticals Inc
Original Assignee
Georgetown University
Samaritan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University, Samaritan Pharmaceuticals Inc filed Critical Georgetown University
Priority to AU2004244982A priority Critical patent/AU2004244982A1/en
Priority to EP04752748A priority patent/EP1631289A4/fr
Priority to JP2006514907A priority patent/JP2006526633A/ja
Priority to CA002527211A priority patent/CA2527211A1/fr
Publication of WO2004108076A2 publication Critical patent/WO2004108076A2/fr
Priority to PCT/US2005/014131 priority patent/WO2005112922A2/fr
Priority to US11/292,797 priority patent/US20060194814A1/en
Anticipated expiration legal-status Critical
Publication of WO2004108076A3 publication Critical patent/WO2004108076A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une méthode thérapeutique de prévention ou de traitement d'une condition ou d'un symptôme pathologique chez un mammifère, tel qu'un homme, pour lequel l'infectivité d'un pathogène tel qu'un rétrovirus à l'égard des cellules de mammifère est impliquée et pour lequel l'inhibition de ladite infectivité est désirée. Cette méthode consiste à administrer à un mammifère nécessitant un tel traitement, une quantité efficace d'un dérivé N-benzamide d'un amide pipérazinyle d'un amino de ce dernier qui présente une infectivité pathogène, y compris ses sels pharmaceutiquement acceptables.
PCT/US2004/015791 2003-06-02 2004-05-20 Composes de benzamide anti-vih Ceased WO2004108076A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2004244982A AU2004244982A1 (en) 2003-06-02 2004-05-20 Anti-HIV benzamide compounds
EP04752748A EP1631289A4 (fr) 2003-06-02 2004-05-20 Composes de benzamide anti-vih
JP2006514907A JP2006526633A (ja) 2003-06-02 2004-05-20 抗ｈｉｖ性ベンズアミド化合物
CA002527211A CA2527211A1 (fr) 2003-06-02 2004-05-20 Composes de benzamide anti-vih
PCT/US2005/014131 WO2005112922A2 (fr) 2004-04-22 2005-04-22 Composes benzamide
US11/292,797 US20060194814A1 (en) 2003-06-02 2005-12-02 Benzamide compounds

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US47496403P 2003-06-02 2003-06-02
US60/474,964 2003-06-02
US47564203P 2003-06-04 2003-06-04
US60/475,642 2003-06-04
US47864803P 2003-08-01 2003-08-01
US60/478,648 2003-08-01
US56463604P 2004-04-22 2004-04-22
US60/564,636 2004-04-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/292,797 Continuation US20060194814A1 (en) 2003-06-02 2005-12-02 Benzamide compounds

Publications (2)

Publication Number Publication Date
WO2004108076A2 WO2004108076A2 (fr) 2004-12-16
WO2004108076A3 true WO2004108076A3 (fr) 2005-12-29

Family

ID=33514877

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/015791 Ceased WO2004108076A2 (fr) 2003-06-02 2004-05-20 Composes de benzamide anti-vih

Country Status (5)

Country Link
EP (1) EP1631289A4 (fr)
JP (1) JP2006526633A (fr)
AU (1) AU2004244982A1 (fr)
CA (1) CA2527211A1 (fr)
WO (1) WO2004108076A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016276A2 (fr) * 2003-08-05 2005-02-24 Samaritan Pharmaceuticals Inc. Ligand du recepteur sigma-1 presentant des proprietes d'inhibition de l'acetylcholinesterase
JP2007531792A (ja) * 2004-04-05 2007-11-08 サマリタン，ファーマスーティカルス，インク． 抗ｈｉｖキヌクリジン化合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3705899A (en) * 1969-05-23 1972-12-12 En Nom Collectif Science Union Benzamidoethyl piperazines
US5908843A (en) * 1993-01-29 1999-06-01 Merck Patent Gesellschaft Mit Beschrankter Haftung Piperazine compounds as fibrinogen inhibitors
US6323223B1 (en) * 1997-08-18 2001-11-27 Syntex (U.S.A.) Llc Cyclic amine derivatives- CCR-3 receptor antagonists
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769578B2 (ja) * 1989-10-13 1998-06-25 大塚製薬株式会社 バソプレシン拮抗剤
GB0030306D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
US20020119979A1 (en) * 2000-10-17 2002-08-29 Degenhardt Charles Raymond Acyclic compounds and methods for treating multidrug resistance
WO2005000205A2 (fr) * 2003-06-02 2005-01-06 Samaritan Pharmaceuticals, Inc. Methodes et compositions permettant de moduler les taux de cortisol serique

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3705899A (en) * 1969-05-23 1972-12-12 En Nom Collectif Science Union Benzamidoethyl piperazines
US5908843A (en) * 1993-01-29 1999-06-01 Merck Patent Gesellschaft Mit Beschrankter Haftung Piperazine compounds as fibrinogen inhibitors
US6323223B1 (en) * 1997-08-18 2001-11-27 Syntex (U.S.A.) Llc Cyclic amine derivatives- CCR-3 receptor antagonists
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1631289A4 *

Also Published As

Publication number Publication date
WO2004108076A2 (fr) 2004-12-16
EP1631289A4 (fr) 2010-06-02
EP1631289A2 (fr) 2006-03-08
JP2006526633A (ja) 2006-11-24
CA2527211A1 (fr) 2004-12-16
AU2004244982A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
CA2883751C (fr) Procedes de traitement de la maladie d'alzheimer et compositions pharmaceutiques associees
CY1120241T1 (el) Χρησιμοποιηση εψιδινης για την παρασκευη ενος φαρμακου για τη θεραπεια διαταραχων της ομοιοστασης του σιδηρου
FI3157527T3 (fi) Ezh2-inhibiittoreita lymfoman hoitoon
EP4424328A3 (fr) Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
TR200101120T2 (tr) Serin proteaz inhibitörü
EA200600820A1 (ru) Способы лечения, модификации и устранения боли с использованием 1-оксо-2-(2,6-диоксопиперидин-3-ил)-4-метилизоиндолина
EA200400881A1 (ru) Азаарилпиперазины
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
SI1546127T1 (sl) Novi pirimidinamidni derivati in njihova uporaba
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
WO2004039325A3 (fr) Compositions contenant un inhibiteur de jnk destinees a traiter, prevenir, gerer et/ou modifier la douleur, et leurs methodes d'utilisation
NO20054714L (no) Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom
WO2005108378A3 (fr) (4-alkylpiperazinyl)(phenyl) methanones
PT1656131E (pt) Utilização de betaína para tratar claudicação intermitente
WO2004108666A3 (fr) Composes de benzoate et de benzamide neuroprotecteurs
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.
PT1362590E (pt) Utilizacao de cilobradina ou dos seus sais farmaceuticamente aceitaveis para o tratamento ou prevencao de falha cardiaca
WO2005112922A3 (fr) Composes benzamide
WO2005089453A3 (fr) Composes de benzamide et de benzoate anti-vih
ATE352317T1 (de) Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen
TW200700075A (en) Roflumilast and integrin inhibitor combination and method of treatment
WO2006085890A3 (fr) Composes de quinuclidine anti-vih

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2527211

Country of ref document: CA

Ref document number: 2004244982

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006514907

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11292797

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004752748

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004244982

Country of ref document: AU

Date of ref document: 20040520

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004244982

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004752748

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11292797

Country of ref document: US